| Novartis Pharma Schweiz AG - Exelon Patch 5, transdermales Pflaster |
| 58078 | | 01 | | Exelon Patch 5 | | transdermales Pflaster | | N06DA03 | | Rivastigmine | | 20.12.2007 | | |
|
| Composition |
| rivastigminum 9 mg, butylis methacrylatis et methylis methacrylatis polymerisatum, acrylic adhesive, int-rac-alpha-tocopherolum, silicone adhesive, dimeticonum, Trägermaterial: poly(ethylenis terephthalas), Drucktinte (Beige): ad praeparationem pro 5 cm², cum liberatione 4.6 mg/24h. |
| Packungsbestandteile |
| Transdermal patch | | | | | Active Agent | Dose |
|---|
| Rivastigmine | 9 mg |
| | BAG: Active Agent | Dose |
|---|
| Rivastigmine | 9 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Acrylic Adhesive | | | | Butylis Methacrylatis | | | | Cum Liberatione | 4.6mg / 24h | | | Dimeticone | | | | Drucktinte (Beige): ad Praeparationem | 5 cm | | | Int-Rac-Alpha-Tocopherolum | | | | Methylis Methacrylatis Polymerisatum | | | | Poly(Ethylenis Terephthalas) | | Trägermaterial | | Silicone Adhesive | | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 30 plaster(s) | 53.24 | 73.45 | B | SL | No |
|
